Hinge

Early-stage fund for founders, by founders. They have backed over 300 teams since 2011. They mainly invest in the US but also invest globally, 37% of investments have been outside the US.

Invests in companies central to the technology industry and those on the edges of science, society, and culture.

Seed-stage investment firm committed to identifying, financing and developing early stage growth businesses led by promising entrepreneurs.

SF-based venture capital firm investing in science and technology companies solving difficult problems. The firm invests at all stages across a wide variety of sectors. Founders Fund pursues a founder-friendly investment strategy, providing maximum support with minimum interference.

Led by 4 technical GPs who met in engineering at UPenn, Eniac is armed with over 80 years of combined experience building their own companies, and are your active partners and roll up their sleeves to work for you. Their companies enjoy support in biz dev, fundraising, networking, ops, PR, and recruitment.

Early-stage fund with a 15-year track record of investing in innovative early-stage startups across the tech stack.

Led by investors including Chris Sacca, Lowercase Capital is a private equity and venture capital firm specializing in investments in seed/startups.

Social Capital is a venture capital investment firm that partners with entrepreneurs at all stages

Previously called 500 Startups, 500 Global has backed over 5,000 founders representing more than 2,600 companies operating in 80 countries. Their portfolio includes 51 companies valued at over $1 billion and 140 companies valued at over $100 million.

Jake is passionate about helping founders solve the biggest challenges facing our world in healthcare, biology, and sustainability. Jake brings venture and startup experience, having worked across three early-stage funds and a startup accelerator. Prior to 11.2 Capital, Jake helped launch 30Ventures, an early-stage healthcare and biotechnology fund focusing on digital health and precision medicine. Jake was formerly an Associate at gener8tor, a nationally ranked startup accelerator, and Lewis & Clark Ventures, a $125M series A and B growth capital fund in the Midwest. Jake holds a Biochemistry degree and MBA in Finance and Entrepreneurship from University of Wisconsin, where he still advises as a proud Badger alumni.

Shelley has over fifteen years of experience in technology as a software engineer, research scientist, business executive, and venture capitalist. Prior to founding 11.2 Capital, Shelley was formerly EVP of Business Development at Ecoplast Technologies, where she oversaw business development & sales efforts in North America. Previously, Shelley was a Principal at DFJ, where she was actively involved in a number of investments including FeedBurner (acquired by Google for $100M), Flurry (acquired by Yahoo for $240M), PPLive (acquired by Suning for $420M), TicketsNow (acquired by Ticketmaster for $265M), Xfire (acquired by Viacom for $102M), YeePay. Shelley is a techie at heart and holds a BS in Computer Science and Computer Engineering from the University of Missouri, and a PhD in Computer Science from the University of California, Berkeley. She is currently an advisor at Skydeck, ML7 Associate at Creative Destruction Lab, and served on Enigma 2016's program committee.

Andrew Hedin is a partner in Bessemer’s Cambridge office. Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund where he invested in early-stage biotech and digital health technologies, as well as Leerink Partners as an advisor to the biopharma industry. He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.

Steve is a partner at Bessemer in the Cambridge office and a world-renowned healthcare investor. Prior to joining Bessemer, Steve worked for a growth-stage, private equity firm and as a management consultant at Bain & Company. He has also worked on several different political campaigns throughout his career. He serves as an Observer at Beth Israel Deaconess Medical Center, an advisor to Boston Children’s Hospital and the Harvard Business School’s Center for Entrepreneurship, and on the investment committees of BCBS Massachusetts and Rock Health.

Kevin Colleran is the Co-Founder and Managing Director at Slow Ventures.